Technology company Kromek (LON: KMK) saw shares sink nearly 10 percent on Wednesday, after recording a £1.5 million loss for the year to April 2017.

The company, who focus on the medical, security screening and nuclear markets, saw revenue increase 7.5 percent to £9 million, with product sales accounting for 74 percent of total revenues.

The company still recorded a £1.5 million EBITDA loss for the year, an improvement on the £2.4 million loss seen last year, with loss before tax for the year was £3.8 million. This came despite attracting further investment of £3.5 million.

The company provides radiation detection products for the medical, security screening and nuclear markets, based on cadmium zinc telluride and other advanced technologies.

Shares in Kromek are currently trading down 9.13 percent at 32.83 (1058GMT).